Advert for Healthcare Professionals Only
Drug Class Description
Salicylates.Generic Name
MesalazineDrug Description
Mesalazine 250mg.Presentation
Enteric coated tabletIndications
Treatment of mild to moderate acute exacerbations of ulcerative colitis and for the maintenance of remission of ulcerative colitisAdult Dosage
Method of Administration: Oral
Adults: Acute treatment: six tablets daily in three divided doses.
Maintenance Treatment: three to six tablets daily in divided doses.
Child Dosage
Not recommended.Elderly Dosage
As for adults
Contra Indications
Hypersensitivity to salicylates, severe renal and hepatic disease, active peptic ulcer, blood clotting abnormalities. Renal impairment. Pregnancy. Advise patients to report any unexplained bleeding, bruising, sore throat or malaise; perform blood test if suspect blood dyscrasia.
Special Precautions
Serious blood dyscrasias have been reported very rarely with mesalazine. Haematological investigations should be performed if the patient develops unexplained bleeding, bruising, purpura, anaemia, fever or sore throat.
Reports of interstitial nephritis occurring with mesalazine treatment are uncommon, however it is advisable that renal function be monitored, with serum creatinine levels measured prior to treatment start, every 3 months for the first year, 6 monthly for the next 4 years, and then annually thereafter. Use with extreme caution in patients with mild to moderate renal impairment. If dehydration develops, normal electrolyte levels and fluid balance should be restored as soon as possible.
Treatment should be stopped if there is suspicion or evidence of blood dyscrasia, or if renal function deteriorates
Interactions
Sulphonylureas, coumarin, methotrexate, probenicid, sulfinpyrazone (sulphinpyrazone), spironolactone, frusemide (furosemide), rifampicin, glucocorticoids.
Adverse Reactions
Hypersensitivity reactions, increased metahaemoglobin levels, blood dyscrasias, headache, GI disturbances, hair loss.Manufacturer
Dr. Falk Pharma UK LtdDrug Availability
(POM)Updated
09 June 2009